Drugmaker Valeant Pharmaceuticals, a fast-growing Wall Street darling until its price-hiking business strategy made it a symbol of pharmaceutical company greed, said it’s undergoing a restructuring as its new CEO attempts to return the debt-laden company to growth and respectability — without big price increases. The maker of Bausch & Lomb contact...